

UTILITY PATENT APPLICATION TRANSMITTAL

(For new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

GM50050C2

First Named Inventor

Konstantinidis, et al.

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER **EV 332 944 058 US** DATE OF DEPOSIT: **23 September 2003**
I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service
"Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:
COMMISSIONER FOR PATENTS, MAIL STOP: PATENT APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.
NAME OF PERSON MAILING PAPER OR FEE Emma Dennis SIGNATURE Emma Dennis
(TYPE OR PRINT)

03914 U.S. PTO
10/668588

09/23/03

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>		7. <input checked="" type="checkbox"/> The Title of the Invention: Methods of Modulating FabH Activity	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. <u>19-2570</u> <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) (Submit an original, and a duplicate for fee processing)		8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input checked="" type="checkbox"/> Use the identical computer-readable form filed in Application No. <u>10/443,432</u> , filed 22 May 2003, as the computer-readable form for the instant application. (37 CFR 1.821(e))	
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$750.00 Total Claims 22 - 20 = 2 x \$18 \$ 36.00 Independent Claims 14 - 3 = 11 x \$84 \$924.00 <input type="checkbox"/> Multiple Dependent Claim present. \$280 TOTAL FILING FEE \$1,710.00 <input type="checkbox"/> Cancel in this application original claims to of the prior application before calculating the filing fee. <input checked="" type="checkbox"/> Charge \$1,710.00 to the above indicated Deposit Account.		ACCOMPANYING APPLICATION PARTS 9. a. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations 10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 11. <input checked="" type="checkbox"/> Prior Application is Assigned to: <u>SmithKline Beecham Corporation and</u> <u>SmithKline Beecham p.l.c.</u> (for continuation/divisional with Box 17a completed) 12. <input checked="" type="checkbox"/> Preliminary Amendment [Total Pages] 3	
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] 46 3b. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] 1		13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] _____		14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] 3 a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17a completed) c. <input type="checkbox"/> Unsigned Declaration [Note Box 6 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. <u>10/443,432</u> filed <u>22 May 2003</u> . A PTO-1449 listing the references is enclosed. 16. <input type="checkbox"/> Other: _____	
6. <input checked="" type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.			

17. <input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information	
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>10/443,432</u> , filed 22 May 2003.	
b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed	
c. ** Add claim to priority via Preliminary Amendment.	

Correspondence Address:	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 (610) 270-4478 Fax (610) 270-5090	Signature Name	Respectfully Submitted, <u>Edward R. Gimmi</u>
Telephone		Registration No.	<u>38,891</u>

20462

PATENT TRADEMARK OFFICE

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EV 332 944 058 US
DATE OF DEPOSIT 23 September 2003

Attorney Docket No.: GM50050C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Konstantinidis, <i>et al.</i>	23 September 2003
Serial No.:	To Be Assigned	Group Art Unit No.: Unknown
Filed:	Herewith	Examiner: Unknown
For:	Methods of Modulating FabH Activity	

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**


Commissioner for Patents
Mail Stop: Patent Application
P.O. Box 1450
Alexandria, Va 22313-1450

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and (e), respectively, are the same.
- (X) I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)** does not include new matter.
- () I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**, included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.

Serial No.: To Be Assigned
Group Art Unit No.: Unknown

- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, is identical to that originally filed.

Respectfully submitted,



Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\ERG\APPS\micro\50050\C2\21statsupp.doc